These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 9564684)

  • 1. Lack of association between debrisoquine 4-hydroxylase (CYP2D6) gene polymorphisms and schizophrenia.
    Jönsson EG; Dahl ML; Roh HK; Jerling M; Sedvall GC
    Psychiatr Genet; 1998; 8(1):25-8. PubMed ID: 9564684
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Debrisoquine 4-hydroxylase (CYP2D6) genetic polymorphisms and susceptibility to schizophrenia in Chinese patients from Taiwan.
    Chen CH; Hung CC; Wei FC; Koong FJ
    Psychiatr Genet; 2001 Sep; 11(3):153-5. PubMed ID: 11702057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic polymorphisms for drug metabolism (CYP2D6) and tardive dyskinesia in schizophrenia.
    Kapitany T; Meszaros K; Lenzinger E; Schindler SD; Barnas C; Fuchs K; Sieghart W; Aschauer HN; Kasper S
    Schizophr Res; 1998 Jul; 32(2):101-6. PubMed ID: 9713905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low frequency of CYP2D6 poor metabolizers among schizophrenia patients.
    Llerena A; Dorado P; Peñas-Lledó EM; Cáceres MC; De la Rubia A
    Pharmacogenomics J; 2007 Dec; 7(6):408-10. PubMed ID: 17325735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An association study of debrisoquine hydroxylase (CYP2D6) polymorphisms in schizophrenia.
    Dawson E; Powell JF; Nöthen MM; Crocq MA; Lanczik M; Körner J; Rietschel M; van Os J; Wright P; Gill M
    Psychiatr Genet; 1994; 4(4):215-8. PubMed ID: 7712118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tardive dyskinesia and debrisoquine 4-hydroxylase (CYP2D6) genotype in Japanese schizophrenics.
    Ohmori O; Suzuki T; Kojima H; Shinkai T; Terao T; Mita T; Abe K
    Schizophr Res; 1998 Jul; 32(2):107-13. PubMed ID: 9713906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. No association between schizophrenia and polymorphisms within the genes for debrisoquine 4-hydroxylase (CYP2D6) and the dopamine transporter (DAT).
    Daniels J; Williams J; Asherson P; McGuffin P; Owen M
    Am J Med Genet; 1995 Feb; 60(1):85-7. PubMed ID: 7485241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytochrome P450 II D6 gene polymorphisms and the neuroleptic-induced extrapyramidal symptoms in Japanese schizophrenic patients.
    Inada T; Senoo H; Iijima Y; Yamauchi T; Yagi G
    Psychiatr Genet; 2003 Sep; 13(3):163-8. PubMed ID: 12960748
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic analysis of the CYP2D6 locus in a Hong Kong Chinese population.
    Garcia-Barceló M; Chow LY; Chiu HF; Wing YK; Lee DT; Lam KL; Waye MM
    Clin Chem; 2000 Jan; 46(1):18-23. PubMed ID: 10620567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuroleptic malignant syndrome and hydroxylase gene mutations: no association with CYP2D6A or CYP2D6B.
    Kawanishi C; Hanihara T; Maruyama Y; Matsumura T; Onishi H; Inoue K; Sugiyama N; Suzuki K; Yamada Y; Kosaka K
    Psychiatr Genet; 1997; 7(3):127-9. PubMed ID: 9323326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Debrisoquine hydroxylase (CYP2D6) and prostate cancer.
    Febbo PG; Kantoff PW; Giovannucci E; Brown M; Chang G; Hennekens CH; Stampfer M
    Cancer Epidemiol Biomarkers Prev; 1998 Dec; 7(12):1075-8. PubMed ID: 9865424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CYP2D6 genotyping in patients on psychoactive drug therapy.
    Topić E; Stefanović M; Ivanisević AM; Blazinić F; Culav J; Skocilić Z
    Clin Chem Lab Med; 2000 Sep; 38(9):921-7. PubMed ID: 11097351
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CYP2D6 genotype and antipsychotic-induced extrapyramidal side effects in schizophrenic patients.
    Scordo MG; Spina E; Romeo P; Dahl ML; Bertilsson L; Johansson I; Sjöqvist F
    Eur J Clin Pharmacol; 2000 Dec; 56(9-10):679-83. PubMed ID: 11214775
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of association in Japanese patients between neuroleptic malignant syndrome and a debrisoquine 4-hydroxylase genotype with low enzyme activity.
    Kawanishi C; Furuno T; Onishi H; Sugiyama N; Suzuki K; Matsumura T; Ishigami T; Kosaka K
    Psychiatr Genet; 2000 Sep; 10(3):145-7. PubMed ID: 11204351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel mutant variant of the CYP2D6 gene (CYP2D6*17) common in a black African population: association with diminished debrisoquine hydroxylase activity.
    Masimirembwa C; Persson I; Bertilsson L; Hasler J; Ingelman-Sundberg M
    Br J Clin Pharmacol; 1996 Dec; 42(6):713-9. PubMed ID: 8971426
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CYP2D6 polymorphism: implications for antipsychotic drug response, schizophrenia and personality traits.
    Dorado P; Peñas-Lledó EM; Llerena A
    Pharmacogenomics; 2007 Nov; 8(11):1597-608. PubMed ID: 18034624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The influence of the CYP2D6 polymorphism on psychopathological and extrapyramidal symptoms in the patients on long-term antipsychotic treatment.
    Plesnicar BK; Zalar B; Breskvar K; Dolzan V
    J Psychopharmacol; 2006 Nov; 20(6):829-33. PubMed ID: 16478753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phenotype and genotype analysis of debrisoquine hydroxylase (CYP2D6) in a black Zimbabwean population. Reduced enzyme activity and evaluation of metabolic correlation of CYP2D6 probe drugs.
    Masimirembwa C; Hasler J; Bertilssons L; Johansson I; Ekberg O; Ingelman-Sundberg M
    Eur J Clin Pharmacol; 1996; 51(2):117-22. PubMed ID: 8911874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polymorphisms of the CYP2D6 gene increase susceptibility to ankylosing spondylitis.
    Brown MA; Edwards S; Hoyle E; Campbell S; Laval S; Daly AK; Pile KD; Calin A; Ebringer A; Weeks DE; Wordsworth BP
    Hum Mol Genet; 2000 Jul; 9(11):1563-6. PubMed ID: 10861282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene polymorphism influencing treatment response in psychotic patients in a naturalistic setting.
    Alenius M; Wadelius M; Dahl ML; Hartvig P; Lindström L; Hammarlund-Udenaes M
    J Psychiatr Res; 2008 Sep; 42(11):884-93. PubMed ID: 18086475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.